PURA Anticipates EVERx CBD Sports Water Sales To Continue Growing In 2021
January 27, 2021 at 11:59 AM EST
Dallas, TX, January 27, 2020 – OTC PR WIRE – Puration, Inc. (OTC PINK: PURA) today announced sales of the company’s EVERx CBD Sports Water remain strong. The company reported over $2 million in annual sales in 2019 and anticipates exceeding $2 million in sales for 2020 after reporting $1.9 million through Q3 2020. With EVERx sales remaining resilient in the face of COVID-19 challenges to the global economy, PURA management anticipates continued EVERx CBD Sports Water sales growth in 2021.
PURA owns a license to a U.S. Patented cannabis extraction process backed by extensive university medical research. The license, issued by NCM Biotech, is exclusive for beverages, edibles and cosmetics among other uses. NCM Biotech is focused on medical research and Puration has access to that research.
Alkame Holdings, Inc. (OTC PINK: ALKM) currently bottles PURA’s EVERx CBD Sports Water. As part of a growing partnership, PURA has recently acquired a five percent stake in ALKM. In conjunction with that growing partnership, ALKM and PURA plan to pilot the production of multiple new CBD infused consumer products.
ALKM and PURA recently announced the two companies plan to produce and test market a CBD infused liquid sugar, a CBD infused pet food supplement and a CBD sexual wellness flavored lubricant.
For more information on Puration, visit http://www.purationinc.com
About West Coast Co Packer, Inc.
About Alkame Holdings, Inc.
For more information, visit www.alkameholdingsinc.com.
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company’s contracts, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.